Literature DB >> 1825622

Homocysteine and the methotrexate toxicity in trisomy 21.

J Lejeune, M Peeters, M O Rethore, M C de Blois.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1825622     DOI： 10.1007/bf00685122

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  12 in total

1.  Methotrexate sensitivity in Down's syndrome: a hypothesis.

Authors:  P M Ueland; H Refsum; B Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  [Metabolism of monocarbons and trisomy 21: sensitivity to methotrexate].

Authors:  J Lejeune; M O Rethoré; M C de Blois; C Maunoury-Burolla; M Mir; L Nicolle; F Borowy; E Borghi; D Recan
Journal:  Ann Genet       Date:  1986

3.  Is absence of atheroma in Down syndrome due to decreased homocysteine levels?

Authors:  B Chadefaux; I Ceballos; M Hamet; M Coude; M Poissonnier; P Kamoun; D Allard
Journal:  Lancet       Date:  1988-09-24       Impact factor: 79.321

4.  Toxicity of leukaemia therapy in children with Down syndrome.

Authors:  M A Peeters; A Poon; A Zipursky; J Lejeune
Journal:  Lancet       Date:  1986-11-29       Impact factor: 79.321

5.  Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia.

Authors:  J Blatt; V Albo; W Prin; S Orlando; M Wollman
Journal:  Lancet       Date:  1986-10-18       Impact factor: 79.321

6.  [Biochemical investigations and trisomy 21 (author's transl)].

Authors:  J Lejeune
Journal:  Ann Genet       Date:  1979-06

7.  Assignment of the gene for cystathionine beta-synthase to human chromosome 21 in somatic cell hybrids.

Authors:  F Skovby; N Krassikoff; U Francke
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

8.  Cystathionine beta synthase: gene dosage effect in trisomy 21.

Authors:  B Chadefaux; M O Rethoré; O Raoul; I Ceballos; M Poissonnier; S Gilgenkranz; D Allard
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

9.  Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity.

Authors:  M Peeters; A Poon
Journal:  Eur J Pediatr       Date:  1987-07       Impact factor: 3.183

10.  Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Authors:  M L Garré; M V Relling; D Kalwinsky; R Dodge; W R Crom; M Abromowitch; C H Pui; W E Evans
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406
View more
  1 in total

1.  Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status.

Authors:  Henri Blehaut; Clotilde Mircher; Aimé Ravel; Martine Conte; Veronique de Portzamparc; Gwendael Poret; Françoise Huon de Kermadec; Marie-Odile Rethore; Franck G Sturtz
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.